PMID- 30088676
OWN - NLM
STAT- MEDLINE
DCOM- 20191021
LR  - 20191022
IS  - 1520-6777 (Electronic)
IS  - 0733-2467 (Linking)
VI  - 37
IP  - 8
DP  - 2018 Nov
TI  - Menthol ameliorates voiding dysfunction in types I and II diabetic mouse model.
PG  - 2510-2518
LID - 10.1002/nau.23785 [doi]
AB  - AIMS: Overactive bladder (OAB) is one of the most common complications of both 
      type 1 (T1DM) and type 2 diabetes mellitus (T2DM). In healthy conditions, menthol 
      infused intravesically reduces the threshold for initiating micturition reflex, 
      but no study evaluated its effects in diabetic conditions. Therefore, we have 
      used mouse models of T1DM and T2DM to evaluate the effects of menthol on 
      cystometric alterations and increased bladder contractility in vitro. METHODS: 
      For T1DM induction, male C57BL6 mice were injected with streptozotocin (STZ) and 
      evaluated after 4 weeks. For T2DM induction, mice were fed with high-fat diet 
      (HFD) for 12 weeks to induce obesity. Urodynamic profiles were assessed by 
      filling cystometry through the infusion of menthol (100 microM for 30 min) or vehicle 
      (DMSO 0.1%). Contractile responses to carbachol, potassium chloride (KCl), and 
      electrical-field stimulation (EFS) were measured in isolated bladders after 
      20 min incubation with menthol (100 microM) or vehicle. RESULTS: Filling cystometry 
      showed that STZ-injected mice exhibited higher bladder capacity, threshold 
      pressure, and non-voiding contractions (NVCs), which were significantly reduced 
      by menthol infusion. The increased voiding frequency in STZ group were unaffected 
      by menthol. In HFD-fed obese mice menthol significantly attenuated the increased 
      threshold pressure and NVC frequency, but unaffected the changes of voiding 
      frequency. In both STZ-injected and HFD-fed mice, incubation of isolated bladders 
      with menthol normalized the enhanced contractile responses to carbachol, KCl, and 
      EFS stimulation. CONCLUSIONS: Menthol may be a potential pharmacological option 
      for the treatment of OAB as a consequence of T1DM and T2DM.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - de Oliveira, Mariana G
AU  - de Oliveira MG
AUID- ORCID: 0000-0003-2226-2530
AD  - Faculty of Medical Sciences, Department of Pharmacology, University of Campinas, 
      Campinas, Sao Paulo, Brazil.
FAU - Nascimento, Daniel M
AU  - Nascimento DM
AD  - Faculty of Medical Sciences, Department of Pharmacology, University of Campinas, 
      Campinas, Sao Paulo, Brazil.
FAU - Alexandre, Eduardo C
AU  - Alexandre EC
AD  - Faculty of Medical Sciences, Department of Pharmacology, University of Campinas, 
      Campinas, Sao Paulo, Brazil.
FAU - Bonilla-Becerra, Sandra M
AU  - Bonilla-Becerra SM
AD  - Faculty of Medical Sciences, Department of Pharmacology, University of Campinas, 
      Campinas, Sao Paulo, Brazil.
FAU - Zapparoli, Adriana
AU  - Zapparoli A
AD  - Faculty of Medical Sciences, Department of Medicine and Experimental Surgery, 
      University of Campinas, Campinas, Sao Paulo, Brazil.
FAU - Monica, Fabiola Z
AU  - Monica FZ
AD  - Faculty of Medical Sciences, Department of Pharmacology, University of Campinas, 
      Campinas, Sao Paulo, Brazil.
FAU - Antunes, Edson
AU  - Antunes E
AD  - Faculty of Medical Sciences, Department of Pharmacology, University of Campinas, 
      Campinas, Sao Paulo, Brazil.
LA  - eng
GR  - FAPESP, 2017/15175-1/Sao Paulo Research Foundation/International
GR  - CAPES, 1680776/Coordination of Improvement of Higher Education 
      Personnel/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180808
PL  - United States
TA  - Neurourol Urodyn
JT  - Neurourology and urodynamics
JID - 8303326
RN  - 1490-04-6 (Menthol)
RN  - 660YQ98I10 (Potassium Chloride)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Experimental/physiopathology
MH  - Diabetes Mellitus, Type 1/*complications
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diet, High-Fat
MH  - Electric Stimulation
MH  - Male
MH  - Menthol/*therapeutic use
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Obese
MH  - Muscle Contraction/drug effects
MH  - Potassium Chloride/pharmacology
MH  - Urinary Bladder/physiopathology
MH  - Urinary Bladder, Overactive/*drug therapy/*etiology/physiopathology
MH  - Urination Disorders/*drug therapy/*etiology/physiopathology
MH  - Urodynamics
OTO - NOTNLM
OT  - cystometry
OT  - diabetes
OT  - obesity
OT  - streptozotocin
OT  - urinary bladder
EDAT- 2018/08/09 06:00
MHDA- 2019/10/23 06:00
CRDT- 2018/08/09 06:00
PHST- 2018/05/10 00:00 [received]
PHST- 2018/07/03 00:00 [accepted]
PHST- 2018/08/09 06:00 [pubmed]
PHST- 2019/10/23 06:00 [medline]
PHST- 2018/08/09 06:00 [entrez]
AID - 10.1002/nau.23785 [doi]
PST - ppublish
SO  - Neurourol Urodyn. 2018 Nov;37(8):2510-2518. doi: 10.1002/nau.23785. Epub 2018 Aug 
      8.